Nevertheless, clinical trials and practice are trying to identify new clinical uses of PDE5 inhibitors for treating heart failure with pulmonary vascular resistance, pulmonary hypertension secondary to left ventricular HF, and transplantation-related advanced heart failure. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.